National and Kapodistrian University of Athens
Κλινική αξιολόγηση των επιπέδων της β2 - μικροσφαιρίνης με ιδιοπαθή φλεγμονώδη νόσο του εντέρου
Abstract
dc:descriptionB2-Microglobulin (B2-M) is a low molecular weight protein not associated with the immunoglobulins. It is mainly produced by activated T-lymphocytes and macrophages in sites of immunoactivation of the above cells and in locations where acute inflammatory process takes place. B2- Microglobulin is not classified among acute phase proteins and its serum levels do not depend on the hepatic ability for synthesis and secretion. The aim of this study is the evaluation of B2-M serum levels as an index of T-lymphocytes and macrophages activation in patients suffering from ulcerative colitis (UC) and Crohn’s disease (CD), since immunoactivation reflects the degree of activity and severity of the inflammatory response. For this purpose B2-M was measured by an immunoenzymatic method in the serum of 87 patients with UC and 74 patients with CD. Based on widely accepted clinico-laboratory criteria 45% of patients with UC and 75% of patients with CD were classified as moderately or severely ill. The results are summarized and interpreted as follows: 1) in 35,6% of patients with UC abnormal serum levels of B2-M were detected. Fifty percent of patients with severe disease had elevated levels of serum B2-M whereas in 40% and 33% of those with moderate and mild disease abnormal levels were measured. Although the above results are indicative of the inflammatory response, these could lead to over-or underestimation regarding disease severity, 2) in 78,4% of patients suffering from CD raised levels of B2-M in the serum were detected. In the group of patients with severe disease 90,9% had elevated levels of B2-M. In the groups of patients with moderate and mild or quiescent disease the percentage was 84,8% and 52,6% accordingly. Moreover, regarding the location of the disease high percentages of abnormal B2-M serum levels were measured in patients with pancolitis (83,3%), in those with caecalileal involvement (84,6%) and finally in those where the disease affected the small bowel (86,3%). Based on recent data, constant immunoactivation of T-lymphocytes and macrophages in inflammation sites could explain all the above results. In conclusion this study shows that the evaluation of serum B2-M especially in patients with CD could become an additional diagnostic tool for the estimation of the inflammatory reaction, regarding early diagnosis and disease recurrence.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2002
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Zissis, Miltiadis
- Ζήσης, Μιλτιάδης
Subjects
dc:subject × 14- Β_2 Μικροσφαιρίνη
- Έντερα, Ιδιοπαθής φλεγμονώδης πάθηση των
- Ελκώδης κολίτιδα
- Νόσος του Crohn
- Δείκτης βαρύτητας - Δραστηριότητες
- Serum B2 microglobulin
- Inflammatory bowel diseases (IBD)
- Ulcerative colitis
- Crohn's disease
- Severity - Activity - Marker
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/20739